Last Updated : July 24, 2024
Details
Generic Name:
mepolizumab
Project Status:
Not filed
Therapeutic Area:
Eosinophilic granulomatosis with polyangiitis
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Nucala
Project Line:
Reimbursement Review
Project Number:
NS0018-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
As an add-on to corticosteroids for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024